Solid Biosciences Inc.

SLDBSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1707502

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues	—	—	$13.6M	$0.00	$0.00
Research and Development Expense	$76.6M	$58.7M	$64.9M	$94.7M	$58.0M
Operating Expenses	$104.3M	$85.9M	$88.4M	$119.3M	$75.7M
Operating Income (Loss)	-$104.3M	-$72.3M	-$88.4M	-$119.3M	-$75.7M
Nonoperating Income (Expense)	$8.2M	$66.0K	$116.0K	$2.1M	$889.0K
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	—	—	—	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$164.9M	$260.3M	$232.4M	$171.2M	$103.5M
Assets, Current	$129.7M	$219.6M	$222.6M	$158.9M	$86.3M
Cash and Cash Equivalents, at Carrying Value	$74.0M	$119.1M	$76.0M	$86.4M	$86.4M
Liabilities	$38.5M	$48.6M	$24.2M	$39.1M	$23.4M
Liabilities, Current	$14.5M	$22.5M	$23.6M	$24.5M	$18.3M
Accounts Payable, Current	$2.0M	$3.2M	$4.5M	$3.3M	$7.1M
Stockholders' Equity Attributable to Parent	$211.7M	$211.7M	$208.2M	$132.1M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$94.2M	-$77.8M	-$56.6M	-$92.7M	-$70.2M
Net Cash Provided by (Used in) Investing Activities	$9.7M	-$91.1M	$6.6M	$24.5M	-$26.8M
Net Cash Provided by (Used in) Financing Activities	$3.1M	$135.0M	$128.7M	$57.9M	$131.5M
Payments to Acquire Property, Plant, and Equipment	$1.5M	$1.3M	$899.0K	$4.4M	$7.8M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)